^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    GPC3 positive

    i
    Other names: GPC3, DGSX, OCI-5, SDYS, SGB, SGBS, SGBS1, Glypican 3
    Entrez ID:
    2719
    Related biomarkers:
    Expression
    4ms
    Radiomic Analysis of Contrast-Enhanced CT Predicts Glypican 3-Positive Hepatocellular Carcinoma. (PubMed, Curr Med Imaging)
    A combined model including AP Rad-score and serum AFP levels based on contrast-enhanced CT could preoperatively predict GPC3-positive expression in HCC.
    Journal • IO biomarker
    |
    AFP (Alpha-fetoprotein) • GPC3 (Glypican 3)
    |
    GPC3 expression • GPC3 positive
    11ms
    Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=33, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting | N=106 --> 33 | Trial completion date: Dec 2030 --> Dec 2025 | Trial primary completion date: Dec 2030 --> Dec 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • GPC3 (Glypican 3)
    |
    GPC3 expression • GPC3 positive
    |
    Tecentriq (atezolizumab) • SAR444200
    1year
    Use of Albumin In Situ Hybridization to Diagnose Cutaneous Metastatic Hepatocellular Carcinoma With Poorly Differentiated Features: A Case Report and Review of the Literature. (PubMed, Am J Dermatopathol)
    Metastatic HCC is a rare encounter for dermatopathologists. We aim to increase awareness of its occurrence in patients with advanced HCC and highlight the importance of clinical correlation when faced with poorly differentiated or unusual-looking basaloid neoplasms.
    Review • Journal • Metastases
    |
    AFP (Alpha-fetoprotein) • GPC3 (Glypican 3)
    |
    GPC3 positive
    1year
    IIT trial of chimeric antigen receptor T cells targeting Glypican-3 in treatment of advance hepatocellular carcinoma (ChiCTR2400083608)
    P=N/A, N=12, Not yet recruiting, The First People's Hospital of Lianyungang; The First People's Hospital of Lianyungang | Initiation date: May 2024 --> Sep 2024
    Trial initiation date • CAR T-Cell Therapy
    |
    AFP (Alpha-fetoprotein) • GPC3 (Glypican 3)
    |
    GPC3 positive
    1year
    [68Ga]Ga-RAYZ-8009: A Glypican-3-Targeted Diagnostic Radiopharmaceutical for Hepatocellular Carcinoma Molecular Imaging-A First-in-Human Case Series. (PubMed, J Nucl Med)
    Thereby, [68Ga]Ga-RAYZ-8009 is promising for HCC diagnosis and staging. Further research is warranted.
    P1 data • Journal
    |
    GPC3 (Glypican 3)
    |
    GPC3 positive
    over1year
    GPC3-targeted CAR-T cells expressing GLUT1 or AGK exhibit enhanced antitumor activity against hepatocellular carcinoma. (PubMed, Acta Pharmacol Sin)
    Finally, we revealed that GLUT1 or AGK maintained anti-apoptosis ability in CD8+ T cells via activation of the PI3K/Akt pathway. This finding might identify a therapeutic strategy for advanced HCC.
    Journal • CAR T-Cell Therapy • IO biomarker
    |
    CD8 (cluster of differentiation 8) • GPC3 (Glypican 3) • AGK (Acylglycerol Kinase) • SLC2A1 (Solute Carrier Family 2 Member 1)
    |
    GPC3 positive
    over1year
    Magnetic Nanoparticle-Based Microfluidic Platform for Automated Enrichment of High-Purity Extracellular Vesicles. (PubMed, Anal Chem)
    This chip was further employed in clinical plasma samples and showed that the number of GPC3-positive EVs isolated from hepatocellular carcinoma patients was significantly higher than that of healthy individuals. This ExoCPR chip may provide a promising tool for EV-based liquid biopsy and other fundamental research.
    Journal
    |
    GPC3 (Glypican 3)
    |
    GPC3 positive
    over1year
    Synthesis and preclinical evaluation of a novel probe [18F]AlF-NOTA-IPB-GPC3P for PET imaging of GPC3 positive tumor. (PubMed, Bioorg Chem)
    Furthermore, the tumor-to-organ ratios of [18F]AlF-NOTA-IPB-GPC3P surpassed those of [18F]AlF-GP2633. Our results support the utilization of [18F]AlF-NOTA-IPB-GPC3P as a PET imaging agent targeting the GPC3 receptor for tumor detection.
    Preclinical • Journal
    |
    GPC3 (Glypican 3)
    |
    GPC3 expression • GPC3 positive
    over1year
    ARYA3: T-Cell Therapy (ECT204) in Adults With Advanced HCC (clinicaltrials.gov)
    P2, N=30, Recruiting, Eureka Therapeutics Inc. | Trial completion date: Dec 2027 --> Dec 2026
    Trial completion date • Metastases
    |
    GPC3 (Glypican 3)
    |
    GPC3 expression • GPC3 positive
    |
    cyclophosphamide • Stivarga (regorafenib) • ECT204
    over1year
    ARYA3: T-Cell Therapy (ECT204) in Adults With Advanced HCC (clinicaltrials.gov)
    P2, N=24, Recruiting, Eureka Therapeutics Inc. | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    GPC3 (Glypican 3)
    |
    GPC3 expression • GPC3 positive
    |
    ECT204
    over1year
    ARYA3: T-Cell Therapy (ECT204) in Adults With Advanced HCC (clinicaltrials.gov)
    P2, N=24, Recruiting, Eureka Therapeutics Inc. | Phase classification: P1/2 --> P2
    Phase classification • Metastases
    |
    GPC3 (Glypican 3)
    |
    GPC3 expression • GPC3 positive
    |
    ECT204
    almost2years
    Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma. (PubMed, J Nucl Med)
    Therapeutically, significant and durable tumor regression and survival benefit were achieved with 177Lu- and 225Ac-labeled RAYZ-8009, as single agents and in combination with lenvatinib, in GPC3-positive HCC xenografts. Preclinical in vitro and in vivo data demonstrate the potential of RAYZ-8009 as a theranostic agent for the treatment of patients with GPC3-positive HCC.
    Journal
    |
    GPC3 (Glypican 3)
    |
    GPC3 expression • GPC3 positive
    |
    Lenvima (lenvatinib)